Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

148.18
+3.022.08%
Post-market: 148.180.00000.00%19:30 EDT
Volume:478.04K
Turnover:70.62M
Market Cap:9.59B
PE:143.86
High:150.48
Open:147.18
Low:145.82
Close:145.16
52wk High:160.81
52wk Low:57.90
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.91
T/O Rate:0.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.39
PE(LYR):-72.28

Loading ...

Protagonist Therapeutics CEO Dinesh V. Patel Disposes of Common Shares Worth USD 18.25 Million

Reuters
·
Yesterday

Protagonist Therapeutics announces $300M share repurchase program

TIPRANKS
·
Sep 09

Protagonist Therapeutics Launches USD 300 Million Share Buyback Program

Reuters
·
Sep 09

Protagonist Therapeutics CEO Patel Joins Fireside Chats at Two Investment Bank Conferences

Reuters
·
Sep 02

Protagonist Therapeutics Price Target Raised to $180.00/Share from $153.00 by Barclays

Dow Jones
·
Sep 02

Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), Teladoc (TDOC) and Protagonist Therapeutics (PTGX)

TIPRANKS
·
Sep 01

Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)

TIPRANKS
·
Sep 01

Protagonist Therapeutics' Mimrylo Holds Commercial Potential After FDA Approval, Truist Says

MT Newswires Live
·
Sep 01

Citigroup Raises Protagonist Therapeutics Price Target to $182 From $175, Buy Rating Kept

MT Newswires Live
·
Sep 01

Protagonist Therapeutics price target raised to $170 from $165 at Citizens

TIPRANKS
·
Sep 01

Protagonist Therapeutics' Own Pipeline Seen as Main Long-Term Growth Driver, Wedbush Says

MT Newswires Live
·
Aug 31

Protagonist Therapeutics is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 31

Protagonist Therapeutics (PTGX) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Aug 31

U.S. Research Roundup-Adobe, Braveheart Bio, CACI International

Reuters
·
Aug 31

Protagonist Therapeutics, Inc. : Jefferies Raises Target Price to $171 from $169

THOMSON REUTERS
·
Aug 31

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Why Protagonist Therapeutics (PTGX) Is Down 6.5% After FDA Approval Triggers $275M Milestone Payment

Simply Wall St.
·
Aug 30

Protagonist Says FDA Approves Takeda’s Mimrylo for Polycythemia Vera Erythrocytosis

Reuters
·
Aug 29

US FDA Approves Takeda, Protagonist's Drug for Rare Blood Cancer

Reuters
·
Aug 29

Protagonist Therapeutics Grants Inducement Equity Awards for 7,175 Shares to New Hires at USD 155.1 Strike Price

Reuters
·
Aug 19